Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone.
The value of hyperthermic isolated limb perfusion (HILP) with cisplatin in the management of locally advanced soft tissue sarcomas or metastatic bone sarcoma was studied. Four patients were treated with HILP under mild hyperthermia (39-40 degrees C) with 20-30 mg cisplatin/l perfused limb volume. Toxicity in the perfused limbs was moderate, and the erythema and oedema that occurred resolved spontaneously within 7-14 days as did the slight motor and sensory neuropathy over a longer period of time. Clinically, a reduction of pain was observed in all patients. Two weeks after perfusion, tumour biopsies were taken to evaluate tumour response. Two patients showed a pathological complete response, one patient showed >90% necrosis and one patient showed no response. Currently patients are treated with tumour necrosis factor and melphalan as perfusion agents. The above-mentioned results make the combination of tumour necrosis factor with cisplatin in the isolated limb perfusion setting an interesting option.
van Ginkel
R J
RJ
Department of Surgical Oncology, University Hospital Groningen, the Netherlands.
Schraffordt Koops
H
H
de Vries
E G
EG
Molenaar
W M
WM
Uges
D R
DR
Hoekstra
H J
HJ
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000628:therapy*
D000970:Antineoplastic Agents; D002945:Cisplatin